Skip to content

Life Sciences

EU export starts with the marketing authorisation holder

  • Life Sciences
  • 1 min read

A manufacturer in Viet Nam cannot hold an EU marketing authorisation in its own name. The holder has to be established in the EEA.

EU law says so directly. Directive 2001/83/EC grants a marketing authorisation only to an applicant established in the Union, and Regulation (EC) No 726/2004 says the same for the centralised procedure. The EEA agreement extends this to Iceland, Liechtenstein and Norway.

For a plant planning EU export, that makes the marketing authorisation holder (MAH) one of the first decisions on the roadmap, well before the dossier is written. The MAH carries legal responsibility for the product on the EU market: variations, pharmacovigilance, and the arrangement with the Qualified Person who certifies batches for release in the EU. A factory can pass an EU GMP inspection and still sell nothing if nobody in the EEA is willing and able to take that role.

The practical routes are an EEA partner who holds the authorisation and contracts the site, an EEA subsidiary, or acquiring an existing authorisation and transferring manufacture to the new site. Each one changes the timeline, the dossier and who controls the product.

Humiley's EU-GMP roadmap consulting covers QMS, CTD/eCTD dossier, technology transfer, MAH, QP and pharmacovigilance. The MAH question usually comes first.

See how we work

Industries

Related

More on this subject

GEP: what qualification can rely on, and what it repeats

Good engineering practice is the design review, installation checks and commissioning that sit under qualification. WHO's HVAC guideline defines it, and EU GMP Annex 15 (2015) allows data from outside the manufacturer's own programs if justified and controlled. Commissioning sheets made with calibrated instruments and signed by the person who measured can then be relied on.

InsightRead

Part 11 starts with the predicate rule

Part 11 applies to electronic records that a predicate rule such as 21 CFR 211 requires. For a BMS or EMS, name the rule behind each point: GMP-critical monitoring usually belongs in a validated EMS. For EU export, Annex 11 has no predicate-rule test, so the BMS still needs a risk assessment.

InsightRead

PW and WFI: sampling points are drawn on the P&ID

EU GMP Annex 1 (2022) clause 6.13 expects sampling at all outlets and points of use, worst-case locations considered, and a representative sample of manufacturing water every day. That only works if reachable sample valves, sub-cooler outlets, the loop return and flushing drains are on the P&ID before isometrics.

InsightRead